Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Chief Operating Officer | September 18, 2024 | September 19, 2024 |
| bluebird bio, Inc.BLUE · Entity 78923 | Chief Operating Officer | December 06, 2018 | December 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date September 18, 2024 · Filed September 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 131,636 |
Last balance in matching sequence
After 2024-09-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-09-18 · Sale · Disposed 4,340 · Balance 136,272 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.09 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 114,453 unvested RSUs. Row 2 · 2024-09-18 · Sale · Disposed 4,636 · Balance 131,636 F4: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.09 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 114,453 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.09 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F3: Includes 114,453 unvested RSUs.
F4: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.
bluebird bio, Inc.
Report date December 06, 2018 · Filed December 21, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,625 |
Reported balance
After 2018-12-06 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-12-06 · Exercise / conversion · Acquired 15 · Balance 15,625 F1: This Form 4 amendment is being filed to report the exercise of 15 stock options which was inadvertently omitted from the original Form 4 filed by the reporting person on December 10, 2018. F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. |
| Common StockSEC Table I · non-derivative | Direct | 15,150 |
Reported balance
After 2018-12-06 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2018-12-06 · Sale · Disposed 475 · Balance 15,150 F3: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F4: The range in prices for the transaction reported on this line was $104.01 to $104.29. The average weighted price was $104.1333. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. |
| Common StockSEC Table I · non-derivative | Direct | 14,050 |
Reported balance
After 2018-12-06 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2018-12-06 · Sale · Disposed 1,100 · Balance 14,050 F3: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F5: The range in prices for the transaction reported on this line was $105.50 to $106.49. The average weighted price was $106.1123. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. |
| Common StockSEC Table I · non-derivative | Direct | 13,750 |
Reported balance
After 2018-12-06 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2018-12-06 · Sale · Disposed 300 · Balance 13,750 F3: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017. F6: The range in prices for the transaction reported on this line was $106.51 to $107.42. The average weighted price was $106.7042. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.65 · Expires 2026-12-01 | Direct | 40,647 |
Reported balance
After 2018-12-06 transaction · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · 2018-12-06 · Exercise / conversion · Disposed 15 · Balance 40,647 F1: This Form 4 amendment is being filed to report the exercise of 15 stock options which was inadvertently omitted from the original Form 4 filed by the reporting person on December 10, 2018. F7: This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 amendment is being filed to report the exercise of 15 stock options which was inadvertently omitted from the original Form 4 filed by the reporting person on December 10, 2018.
F2: The reporting person's amount of securities beneficially owned following the reporting transaction is amended to reflect the accurate amount owned.
F3: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 18, 2017.
F4: The range in prices for the transaction reported on this line was $104.01 to $104.29. The average weighted price was $104.1333. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The range in prices for the transaction reported on this line was $105.50 to $106.49. The average weighted price was $106.1123. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The range in prices for the transaction reported on this line was $106.51 to $107.42. The average weighted price was $106.7042. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: This option vests over a four-year period at a rate of twenty-five percent (25%) on November 30, 2017, and in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2024 Filed Sep 19, 2024 20:52 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 4,636 | $34.41 | $159,524.76 |
DisclosureSEC source: 0000950170-24-108154 · ownership.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,636 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.09 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 114,453 unvested RSUs. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 20:52 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 4,340 | $34.41 | $149,339.40 |
DisclosureSEC source: 0000950170-24-108154 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,272 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.09 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 114,453 unvested RSUs. Read SEC document |
| September 11, 2024 Filed Sep 11, 2024 20:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,722 | $31.89 | $86,804.58 |
DisclosureSEC source: 0000950170-24-105512 · ownership.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,612 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.59 to $32.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 123,429 unvested RSUs. Read SEC document |
| September 11, 2024 Filed Sep 11, 2024 20:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,548 | $31.89 | $81,255.72 |
DisclosureSEC source: 0000950170-24-105512 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,334 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.59 to $32.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 123,429 unvested RSUs. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:26 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 328 | $46.00 | $15,088.00 |
DisclosureSEC source: 0000950170-24-099124 · ownership.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,882 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive. F4 · balance_after: Includes 128,699 unvested RSUs. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:26 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,582 | $45.01 | $116,215.82 |
DisclosureSEC source: 0000950170-24-099124 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,210 F1 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 00:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 10,163 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-077029 · ownership.xml · derivative · entry 6 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,536 Underlying: Common Stock · 10,163 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 00:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 10,163 | $35.33 | $359,058.79 |
DisclosureSEC source: 0000950170-24-077029 · ownership.xml · nonDerivative · entry 4 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.60, inclusive. F4 · balance_after: Includes 134,629 unvested RSUs. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 00:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 10,163 | $5.54 | $56,303.02 |
DisclosureSEC source: 0000950170-24-077029 · ownership.xml · nonDerivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2024 Filed Jul 4, 2024 01:00 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 10,213 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-081748 · ownership.xml · derivative · entry 6 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,486 Underlying: Common Stock · 10,213 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein. F6 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| June 24, 2024 Filed Jul 4, 2024 01:00 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 10,213 | $35.33 | $360,825.29 |
DisclosureSEC source: 0000950170-24-081748 · ownership.xml · nonDerivative · entry 4 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F3 · shares: This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.63, inclusive. F5 · balance_after: Includes 134,629 unvested RSUs. Read SEC document |
| June 24, 2024 Filed Jul 4, 2024 01:00 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 10,213 | $5.54 | $56,580.02 |
DisclosureSEC source: 0000950170-24-081748 · ownership.xml · nonDerivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: This Form 4/A is being filed to correct the number of stock options exercised and subsequent shares of common stock sold as reported in Tables I and II of the original Form 4 filed on June 24, 2024, which inadvertently reported 10,163 stock options exercised and subsequent shares of common stock sold instead of the 10,213 shares reported herein. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 00:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 29,787 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-077029 · ownership.xml · derivative · entry 5 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,699 Underlying: Common Stock · 29,787 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 00:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 29,787 | $35.01 | $1,042,842.87 |
DisclosureSEC source: 0000950170-24-077029 · ownership.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 00:41 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 29,787 | $5.54 | $165,019.98 |
DisclosureSEC source: 0000950170-24-077029 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2024 Filed Jul 4, 2024 01:00 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 29,787 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-081748 · ownership.xml · derivative · entry 5 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,699 Underlying: Common Stock · 29,787 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| June 21, 2024 Filed Jul 4, 2024 01:00 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 29,787 | $35.01 | $1,042,842.87 |
DisclosureSEC source: 0000950170-24-081748 · ownership.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. Read SEC document |
| June 21, 2024 Filed Jul 4, 2024 01:00 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 29,787 | $5.54 | $165,019.98 |
DisclosureSEC source: 0000950170-24-081748 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 01:45 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-073289 · ownership.xml · derivative · entry 4 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,486 Underlying: Common Stock · 40,000 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 01:45 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 13,964 | $33.70 | $470,586.80 |
DisclosureSEC source: 0000950170-24-073289 · ownership.xml · nonDerivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $33.51 to $34.04, inclusive. F4 · balance_after: Includes 134,629 unvested RSUs. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 01:45 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 26,036 | $33.17 | $863,614.12 |
DisclosureSEC source: 0000950170-24-073289 · ownership.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,756 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $32.50 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 01:45 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 40,000 | $5.54 | $221,600.00 |
DisclosureSEC source: 0000950170-24-073289 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 23:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,913 | $31.23 | $90,972.99 |
DisclosureSEC source: 0000950170-24-072153 · ownership.xml · nonDerivative · entry 4 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. F5 · balance_after: Includes 134,629 unvested RSUs. Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 23:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,357 | $31.23 | $73,609.11 |
DisclosureSEC source: 0000950170-24-072153 · ownership.xml · nonDerivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,705 F3 · kind: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 80,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000950170-24-072153 · ownership.xml · derivative · entry 5 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,486 Underlying: Common Stock · 80,000 shares Expires 2030-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on July 31, 2021 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 80,000 | $30.24 | $2,419,200.00 |
DisclosureSEC source: 0000950170-24-072153 · ownership.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,062 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.85 to $30.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 80,000 | $5.54 | $443,200.00 |
DisclosureSEC source: 0000950170-24-072153 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2024 Filed May 18, 2024 01:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 489 | $28.59 | $13,980.51 |
DisclosureSEC source: 0000950170-24-062078 · ownership.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,062 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive. F4 · balance_after: Includes 139,899 unvested RSUs. Read SEC document |
| May 16, 2024 Filed May 18, 2024 01:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,249 | $28.20 | $63,421.80 |
DisclosureSEC source: 0000950170-24-062078 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,551 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,292 | $25.70 | $58,904.40 |
DisclosureSEC source: 0000950170-24-030485 · ownership.xml · nonDerivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,800 F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive. F5 · balance_after: Includes 145,829 unvested RSUs. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 291 | $27.41 | $7,976.31 |
DisclosureSEC source: 0000950170-24-030485 · ownership.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,092 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.39 to $27.42, inclusive. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 10:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 26,908 | $26.66 | $717,367.28 |
DisclosureSEC source: 0000950170-24-030485 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,383 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.32 to $27.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,591 | $25.85 | $41,127.35 |
DisclosureSEC source: 0000950170-24-029614 · ownership.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,291 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.84 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 151,099 unvested RSUs. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:34 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,616 | $10.72 | $17,323.52 |
DisclosureSEC source: 0001209191-23-058329 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,882 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 157,029 unvested RSUs. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:30 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 36,952 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001209191-23-055526 · doc4.xml · derivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,952 Underlying: Common Stock · 36,952 shares Expires 2033-11-14 F3 · derivative.exercise_date: This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:30 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 94,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055526 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,498 F1 · shares: Consists of shares of Common Stock issuable under 94,893 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024. F2 · balance_after: Includes 162,299 unvested RSUs. Read SEC document |
| November 02, 2023 Filed Nov 2, 2023 21:16 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 9,939 | $7.40 | $73,548.60 |
DisclosureSEC source: 0001209191-23-054194 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,605 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 10, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $7.12 to $7.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:48 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,672 | $9.41 | $25,143.52 |
DisclosureSEC source: 0001209191-23-050172 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,544 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 67,406 unvested RSUs. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 23:51 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,635 | $10.41 | $17,020.35 |
DisclosureSEC source: 0001209191-23-049359 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,216 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.09 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 76,382 unvested RSUs. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 22:40 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,625 | $12.43 | $20,198.75 |
DisclosureSEC source: 0001209191-23-037166 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,851 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 81,652 unvested RSUs. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 21:50 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,559 | $13.33 | $20,781.47 |
DisclosureSEC source: 0001209191-23-018980 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,476 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 86,922 unvested RSUs. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 22:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 751 | $10.87 | $8,163.37 |
DisclosureSEC source: 0001209191-22-060970 · doc4.xml · nonDerivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,035 F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · balance_after: Includes 92,191 unvested RSUs. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 22:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001209191-22-060970 · doc4.xml · derivative · entry 3 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2032-12-08 F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 22:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 44,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060970 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,786 F1 · shares: Consists of shares of Common Stock issuable under 44,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023. F2 · balance_after: Includes 94,710 unvested RSUs. Read SEC document |
| September 20, 2022 Filed Sep 21, 2022 20:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 2,629 | $13.70 | $36,017.30 |
DisclosureSEC source: 0001209191-22-050888 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,786 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 50,710 unvested RSUs. Read SEC document |
| September 15, 2022 Filed Sep 15, 2022 21:26 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 786 | $14.05 | $11,043.30 |
DisclosureSEC source: 0001209191-22-050120 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,415 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 59,686 unvested RSUs. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 22:19 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 36,219 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001209191-22-041333 · doc4.xml · derivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,219 Underlying: Common Stock · 36,219 shares Expires 2030-07-30 F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 00:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 802 | $4.95 | $3,969.90 |
DisclosureSEC source: 0001209191-22-037146 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,201 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 62,205 unvested RSUs. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 21:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 765 | $8.73 | $6,678.45 |
DisclosureSEC source: 0001209191-22-018535 · doc4.xml · nonDerivative · entry 1 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,003 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.68 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 64,724 unvested RSUs. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:21 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 60,472 | $0.00 Strike: $13.12 | $0.00 |
DisclosureSEC source: 0001209191-21-069423 · doc4.xml · derivative · entry 2 HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,472 Underlying: Common Stock · 60,472 shares Expires 2031-12-09 F3 · derivative.exercise_date: This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.